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Abstract 
      Dyslipidemia is a primary risk factor for cardiovascular disease and  
a common complication of progressive kidney disease leading to increased 
morbidity and mortality in this patients group.  
         This is a prospective, cross- sectional, case series, hospital based study 
during period of six month from December 2006 to May 2007. 
        The aim of our study was to determine the lipid profiles of chronic 
renal failure (CRF) patients and the effect of different modes of management 
in lipid profiles.  
         The mean age of the study group was found to be 11.37 ± 4.2 years, 
48.3% were older than 12 year of age.  Male constituted 62.1% and female 
constituted 37.9% . 
       The study included 4 groups; Group I: healthy controls (n=28).  Group 
II: CRF patients on conservative treatment (n=18), Group III: patients on 
chronic dialysis (n=28), Group IV post renal transplanted (n=12). Out of the 
28 patients on chronic dialysis (Group III) 17 patient were in Haemodialysis 
(HD), and 11 were on Continuous Ambulatory Peritoneal Dialysis (CAPD). 
       The lipid analyzed included total cholesterol, triglyceride (TG), low 
density lipoprotein (LDL), very low density lipoprotein (VLDL) and high 
density lipoprotein (HDL) levels. 
            Elevated (> 95th centile) serum cholesterol level were observed in 
22.2% of group II (conservative), 42.9%of group III (regular dialysis), and 
25% of group VI (transplanted patients).  Elevated serum triglycerides were 
found in 22.2% of group II, 46.4% of group III and in 83.3% of group IV. 
Elevated LDL were found in 33.3% of group II, 39.3% of group III and in 
 iv
16.7% of group IV.   HDL elevated in 27.8% patients of group II, 32.1% of 
group III . 
         The mean of all lipid profiles studied, with the exception of HDL, was 
found to be significantly high compared to control (p value < 0.05).  
        However there was no significant difference in serum lipid profile in 
between patients group. 
When compared the Group II versus Group I, with exception of 
cholesterol and LDL (p = 0.00), there were no significant difference in the 
mean values of the other serum lipid profiles.  
When Group III and Group IV were compared to control, there were 
significant elevation in all serum lipid profiles, with exception of HDL,  (p = 
<0.05).    
       There is an inverse relation between LDL and GFR that is when GFR 
decrease LDL value increase. Also it is found that Serum cholesterol 
increase with increasing in the duration between diagnosis and dialysis. 
         The result of this study was agreed with the few study done in lipid 
profiles in children with chronic renal failure. 
       Evidence from this study suggests that hyperlipidemia exist in 
childhood and adolescence of CRF so early detection and management is 
needed to protect cardiovascular complication.  
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  ﻣﻠﺨﺺ  ﺍﻻﻃﺮﻭﺣﺔ
  
اﻻﺿﻄﺮاب اﻟﺪهﻨﻲ ﻣﻦ اهﻢ اﻟﻌﻮاﻣﻞ اﻻوﻟﻴﺔ اﻟﺘﻲ ﺗﺘﺴﺒﺐ ﻓﻲ اﻻﺻﺎﺑﺔ ﺑﺪاء اﻟﺸﺮاﻳﻴﻦ اﻟﺘﺎﺟﻴﻪ   
  .ﻓﻲ اﻟﻘﻠﺐ وﺗﻌﺘﺒﺮ ﻣﻦ اﻟﻤﻀﺎﻋﻔﺎت اﻟﺸﺎﺋﻌﺔ ﺑﻤﺮض اﻟﻔﺸﻞ اﻟﻜﻠﻮي اﻟﺘﻲ ﻗﺪ ﺗﺘﺴﺒﺐ ﻓﻲ اﻻﻣﺎﺗﻪ 
   .7002 اﻟﻲ ﻣﺎﻳﻮ 6002ﺗﻤﺖ دراﺳﺔ ﻋﻴﻨﻴﺔ ﻧﻤﻮذﺟﻴﻪ ﻓﻲ اﻟﻤﺴﺘﺸﻔﻲ ﻓﻲ اﻟﻔﺘﺮة ﻣﺎﺑﻴﻦ دﻳﺴﻤﺒﺮ   
هﻮ ﺗﺤﺪﻳﺪ اﻧﺘﺸﺎر اﺿﻄﺮاب اﻟﺪهﻮن ﻓﻲ اﻟﺪم ﻓﻲ اﻻﻃﻔﺎل اﻟﻤﺼﺎﺑﻴﻦ ﺑﺎﻟﻔﺸﻞ اﻟﻜﻠﻮي   :هﺪف اﻟﺪراﺳﺔ
  .اﻟﻤﺰﻣﻦ ﻣﻊ ﻣﻘﺎرﻧﺔ ﻧﺴﺒﺔ اﺿﻄﺮاب اﻟﺪهﻮن ﺑﻴﻦ اﻟﻤﺮﺿﻲ اﻟﺬﻳﻦ ﻳﺨﻀﻌﻮن ﺑﻄﺮق ﻋﻼﺟﻴﺔ ﻣﺨﺘﻠﻔﺔ 
 21)ﻣﻨﻬﻢ اآﺒﺮ ﻣﻦ ﻋﻤﺮ % 3.84 ﺑﻨﺴﺒﺔ 2.4 + 73.11ان ﻣﺘﻮﺳﻂ اﻋﻤﺎر اﻟﻤﺼﺎﺑﻴﻦ آﺎﻧﺖ   
  % .9.73 آﻤﺎ ﺷﻜﻠﺖ ﻧﺴﺒﺔ اﻻﻧﺎث -% 1.26وﻗﺪ ﺷﻜﻠﺖ ﻧﺴﺒﺔ اﻟﺬآﻮر  –( ﺳﻨﺔ 
اﻟﻤﺠﻤﻮﻋﺔ ، اﺻﺤﺎء (  ﻃﻔﻞ82)اﻟﻤﺠﻤﻮﻋﺔ اﻻوﻟﻲ :  ﺗﻀﻤﻨﺖ اﻟﺪراﺳﺔ ارﺑﻌﺔ ﻣﺠﻤﻮﻋﺎت   
 ﻃﻔﻞ 71ﻣﻨﻬﻢ (  ﻃﻔﻞ82)اﻟﻤﺠﻤﻮﻋﺔ اﻟﺜﺎﻟﺜﺔ ، .ﺑﺨﻀﻌﻮن ﻟﻠﻌﻼج اﻟﺘﺤﻔﻈﻲ (  ﻃﻔﻞ81)اﻟﺜﺎﻧﻴﺔ 
ﺗﻤﺖ ﻟﻬﻢ (  ﻃﻔﻞ21)ﻔﺎﻗﻴٍﺔ واﻟﻤﺠﻤﻮﻋﺔ اﻟﺮاﺑﻌﺔ  ﻃﻔﻞ ﻟﻠﺪﻳﻠﺰﻩ اﻟﺼ11ﻳﺨﻀﻌﻮن ﻟﻼﺳﺘﺼﻔﺎء اﻟﺪﻣﻮي و 
  . زراﻋﺔ آﻠﻲ
، اﻟﺪهﻮن اﻟﺘﻲ ﺗﻢ ﺗﺤﻠﻴﻠﻬﺎ ﻓﻲ اﻟﺪم اﺷﺘﻤﻠﺖ ﻋﻠﻲ اﻟﻜﻮﻟﻴﺴﺘﺮول واﻟﺠﻠﻴﺴﺮﻳﺪ اﻟﺜﻼﺛﻲ ﻓﻲ اﻟﺪهﻮن   
، اﻻﺿﻄﺮاب اﻟﺪهﻨﻲ ﻓﻲ اﻟﺒﺮوﺗﻴﻦ ﻗﻠﻴﻞ اﻟﻜﺜﺎﻓﺔ ﺟﺪا ، اﻻﺿﻄﺮاب اﻟﺪهﻨﻲ ﻓﻲ اﻟﺒﺮوﺗﻴﻦ ﻗﻠﻴﻞ اﻟﻜﺜﺎﻓﺔ 
  .ﻦ ﻣﺮﺗﻔﻊ اﻟﻜﺜﺎﻓﺔاﻻﺿﻄﺮاب اﻟﺪهﻨﻲ ﻓﻲ اﻟﺒﺮوﺗﻴ
ﻣﻦ اﻟﻤﺠﻤﻮﻋﺔ اﻟﺜﺎﻟﺜﺔ و % 24، ﻣﻦ اﻟﻤﺠﻤﻮﻋﺔ اﻟﺜﺎﻧﻴﺔ % 2.22وﺟﺪت زﻳﺎدة اﻟﻜﻠﻴﺴﺘﺮول ﻓﻲ   
  .ﻣﻦ اﻟﻤﺠﻤﻮﻋﺔ اﻟﺮاﺑﻌﺔ % 52
ﻣﻦ % 4.64ﻣﻦ اﻟﻤﺠﻤﻮﻋﺔ اﻟﺜﺎﻧﻴﺔ و % 2.22آﻤﺎ وﺟﺪت زﻳﺎدة اﻟﺠﻠﻴﺴﺮﻳﺪ اﻟﺜﻼﺛﻲ ﻟﻠﺪهﻮن ﻓﻲ   
ﺎ ﺷﻜﻞ اﻻﺿﻄﺮاب اﻟﺪهﻨﻲ ﻓﻲ اﻟﺒﺮوﺗﻴﻦ ﺑﻴﻨﻤ.  ﻣﻦ اﻟﻤﺠﻤﻮﻋﺔ اﻟﺮاﺑﻌﺔ % 3.38، اﻟﻤﺠﻤﻮﻋﺔ اﻟﺜﺎﻟﺜﺔ 
ﻣﻦ % 7.61ﻣﻦ اﻟﻤﺠﻤﻮﻋﺔ اﻟﺜﺎﻟﺜﺔ و % 3.93، ﻓﻲ اﻟﻤﺠﻤﻮﻋﺔ اﻟﺜﺎﻧﻴﺔ % 3.33ﻗﻠﻴﻞ اﻟﻜﺜﺎﻓﺔ ﻧﺴﺒﺔ 
  .اﻟﻤﺠﻤﻮﻋﺔ اﻟﺮاﺑﻌﺔ 
ﻣﻦ % 1.23ﻣﻦ اﻟﻤﺠﻤﻮﻋﺔ اﻟﺜﺎﻧﻴﺔ و % 8.72اﻣﺎ اﻻﺿﻄﺮاب اﻟﺪهﻨﻲ ﻣﺮﺗﻔﻊ اﻟﻜﺜﺎﻓﺔ وﺟﺪ ﻓﻲ   
  .اﻟﻤﺠﻤﻮﻋﺔ اﻟﺜﺎﻟﺜﺔ 
iv 
هﻨﻲ ﺑﻜﻞ اﻧﻮاﻋﻪ ﻣﺎﻋﺪا ﻓﻲ اﻟﺒﺮوﺗﻴﻦ ﻣﺮﺗﻔﻊ اﻟﻜﺜﺎﻓﺔ آﺎن ﻋﺎﻟﻲ ان ﻣﺘﻮﺳﻂ اﻻﺿﻄﺮاب اﻟﺪ  
  ﺑﻴﻨﻤﺎ ﻟﻢ ﻳﻮﺟﺪ اي ﻓﺮق ﻓﻲ ﻣﺴﺘﻮي اﻻﺿﻄﺮاب اﻟﺪهﻨﻲ -اﻟﻤﺴﺘﻮي ﻓﻲ اﻟﻤﺼﺎﺑﻴﻦ ﻣﻘﺎرﻧﺔ ﻣﻊ اﻻﺻﺤﺎء 
  .ﻣﺎﺑﻴﻦ ﻣﺠﻤﻮﻋﺎت اﻟﻤﺮﺿﻲ 
ﺑﻤﻘﺎرﻧﺔ اﻟﻤﺠﻤﻮﻋﺔ اﻟﺜﺎﻧﻴﺔ ﺑﺎﻻوﻟﻲ ﻟﻢ ﻳﻮﺟﺪ ﻓﺮق ﻓﻲ ﻧﺴﺒﺔ اﻻﺿﻄﺮاب اﻟﺪهﻨﻲ ﺑﻴﻦ   
آﻤﺎ ﺗﻤﺖ .  ﻲ ﻣﺴﺘﻮي اﻻﺿﻄﺮاب اﻟﺪهﻨﻲ ﻓﻲ اﻟﺒﺮوﺗﻴﻦ ﻗﻠﻴﻞ اﻟﻜﺜﺎﻓﺔ واﻟﻜﻠﻴﺴﺘﺮول اﻟﻤﺠﻤﻮﻋﺘﻴﻦ ﻋﺪا ﻓ
ﻣﻘﺎرﻧﺔ اﻟﻤﺠﻤﻮﻋﺔ اﻟﺜﺎﻟﺜﺔ واﻟﺮاﺑﻌﺔ ﻣﻊ اﻟﻤﺠﻤﻮﻋﺔ اﻻوﻟﻲ ﻟﻢ ﻳﻮﺟﺪ ﻓﺮق ﻓﻲ ﻣﺴﺘﻮي اﻻﺿﻄﺮاب اﻟﺪهﻨﻲ 
  .ﻣﺎﻋﺪا ﻓﻲ ﻣﺴﺘﻮي اﻟﻜﻠﻴﺴﺘﺮول 
ﻜﻠﻲ ﻋﻨﺪﻣﺎ ﺗﻘﻞ وﺟﺪت ﻋﻼﻗﺔ ﺳﻠﺒﻴﺔ ﺑﻴﻦ اﻻﺿﻄﺮاب اﻟﺪهﻨﻲ ﻗﻠﻴﻞ اﻟﻜﺜﺎﻓﺔ وﻣﻌﺪل اﻟﺘﺼﻔﻴﺔ ﻟﻠ  
  .ﻧﺴﺒﺔ ﺗﺼﻔﻴﺔ اﻟﻜﻠﻲ ﻳﺰﻳﺪ ﻣﻌﺪل اﻻﺿﻄﺮاب اﻟﺪهﻨﻲ ﻗﻠﻴﻞ اﻟﻜﺜﺎﻓﺔ 
  .واﺗﻀﺢ اﻳﻀﺎ ان ﻧﺴﺒﺔ ﻣﻌﺪل اﻟﻜﻠﻴﺴﺘﺮول ﻳﺰﻳﺪ ﺑﺰﻳﺎدة ﻣﺪة اﻟﻤﺮض   
ﻧﺘﺎﺋﺞ هﺬﻩ اﻟﺪراﺳﺔ ﻗﺪ اﺗﻔﻘﺖ ﻣﻊ ﻋﺪد ﻣﻦ اﻟﺪراﺳﺎت ﻓﻲ اﻻﺿﻄﺮاب اﻟﺪهﻨﻲ ﻋﻨﺪ اﻻﻃﻔﺎل 
  .اﻟﻤﺼﺎﺑﻴﻦ ﺑﺎﻟﻔﺸﻞ اﻟﻜﻠﻮي اﻟﻤﺰﻣﻦ 
راﺳﺔ ان اﻻﺿﻄﺮاب اﻟﺪهﻨﻲ  ﻳﻜﻮن ﺷﺎﺋﻌﺎ ﺑﻴﻦ اﻻﻃﻔﺎل اﻟﻤﺼﺎﺑﻴﻦ ﺑﺎﻟﻔﺸﻞ ﺗﺒﻴﻦ ﻣﻦ هﺬﻩ اﻟﺪ
اﻟﻜﻠﻮي وﻋﻠﻴﻪ اﻻآﺘﺸﺎف اﻟﻤﺒﻜﺮ ﻟﻬﺬا اﻻﺿﻄﺮاب ﻗﺪ ﻳﺴﺎﻋﺪ ﻓﻲ ﺗﻘﻠﻴﻞ اﻣﺮاض اﻟﺸﺮاﻳﻴﻦ اﻟﺘﺎﺟﻴﺔ ﻓﻲ 
  .اﻟﻘﻠﺐ 
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Chapter One 
1- INTRODUCTION AND LITRATURE REVIEW 
1.1 General Introduction: 
    Chronic kidney disease (CKD) is a worldwide health problem. 
There is a rising incidence and prevalence of kidney failure, with a 
poor outcome and at high cost. There is an even higher prevalence of 
earlier stages of chronic kidney disease. 
   The increasing evidence which was gained in the past decades 
indicates that the adverse outcome of chronic kidney disease; such as 
kidney failure, cardiovascular disease, and premature death can be 
prevented or delayed.  
   `The early treatment of chronic kidney disease is effective in slowing 
the progression towards kidney failure. Another advantage is 
decreasing the risk for cardiovascular disease both before and after the 
onset of kidney failure (1) .        
     `The association between lipids and kidney disease was first 
noted by Virchow, who described” fatty degeneration “of the renal 
epithelium in Brights disease in 1860(2).  Since then the possible 
adverse effects of dyslipidemias complicating renal disease have 
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attracted the interest of many investigators and both qualitative and 
quantitative abnormalities in lipid profiles have been noted in patient 
with chronic renal failure (3) . 
1.2    Definition and Classification of CKD: 
 The Kidney Disease Outcomes Quality Initiative (K/DOQI) of 
the US National Kidney Foundation (NKF) defines chronic kidney 
disease as either a kidney damage or a decreased kidney glomerular 
filtration rate(GFR) of <60 mL/min/1.73 m2 for 3 or more months.  
      Whatever is the underlying etiology, the destruction of renal 
mass with irreversible sclerosis and loss of nephrons leads to   
progressive decline in the GFR.  
In 2002 K/DOQI published a classification for the stages of 
CKD as following: 
? Stage 1: Kidney damage with a normal or an increased GFR 
(>90 mL/min/1.73 m2)  
? Stage 2: Mild reduction in GFR (60-89 mL/min/1.73 m2)  
? Stage 3: Moderate reduction in GFR (30-59 mL/min/1.73 m2)  
? Stage 4: Severe reduction in GFR (15-29 mL/min/1.73 m2) 
? Stage 5: Kidney failure (GFR <15 mL/min/1.73 m2) or 
dialysis(4) . 
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 Another classification based on the percentages of the residual 
renal function, symptoms and metabolic abnormalities divides CKD 
into   four stages: (5) 
 
 
Stage 
Residual renal   
function % 
Symptom or metabolic 
abnormalities 
Impaired renal 
function (IRF) 
 
40—80 
 
Non 
Chronic renal 
insufficiency 
(CRI) 
 
25—50 
 
Asymptomatic, short 
stature ect 
CRF  
<30 
Acidosis, anemia, BP, 
lethargy 
ESRD Usually<10 Dialysis is needed 
     
The term impaired renal function (IRF) refers to an individual 
who is asymptomatic and has a renal function of 40% - 80% of 
normal. The term CRI is associated with a residual renal function of 
25% - 50% of normal. At this level of the renal function, distinct 
biochemical abnormalities may present only when the patient is 
stressed. 
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     The term CRF is used to describe a patient with a residual renal 
function of < 30%. Patients with CRF exhibit biochemical 
abnormalities even when not stressed. ESRD is a term used when 
dialysis or transplantation is required.  
    Uremia is a syndrome complex that includes anorexia, nausea, 
itching, neuropathy and malaise. This complex is not associated with 
any special concentration of urea in the blood, but is usually 
considered the last stage of renal failure (5) . 
1.3 Prevalence of Chronic Renal Failure: 
1.3.1 Prevalence of chronic renal failure worldwide:    
         Chronic kidney diseases represent a new and rapidly developing 
worldwide threat, according to the International Society of 
Nephrology (ISN), more than 1 million people around the world are 
alive on renal dialysis, and according to the National Kidney 
Foundation, the incidence and prevalence of kidney failure have 
doubled in the last 15 years and is expected to continue to increase (6).  
In a study done in Italy, by December 2000 the mean incidence was 
12.1 cases per million, and the prevalence was 74.7 per million of <20 
yrs population(7) (8) . 
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1.3.2 Prevalence of chronic renal failure in Arab world: 
The prevalence of chronic renal failure is high in the Arab 
world. Data available on the exact prevalence of various renal 
diseases are very limited. Nevertheless, the reported prevalence of 
chronic renal failure is 80 - 120 per million population (PMP) in the 
Kingdom of Saudi Arabia and 225 PMP in Egypt. This is in 
comparison with the reported prevalence of 283 PMP in Europe, 97 
PMP in the United States and 1149 PMP in Japan (7). 
The lower prevalence rates reported in Arab region could be 
due to underreporting (8) .  Over 8years (January 1996 - December 
2003) the mean incidence rate of CRF in Kuwaiti children was found 
to be 38.2 per million children per year (9) . 
1.3.3   Prevalence of chronic renal failure in Africa:  
The incidence of renal disease is much higher in Africa than 
that in the West, yet the prevalence is relatively lower, which mirrors 
the inadequacy of medical care facilities (10). 
       Barsoum in his review of ESRD in North Africa countries            
(Morocco, Algeria, Tunisia, Libya and Egypt,)   reported an annual 
incidence of ESRD that ranges between 34 – 200 PMP. (10) The 
incidence of ESRD in children in Tunisia was estimated as 7 per 
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million children per year with a male: female ratio of 1.83:1 (11) . 
Ekeetal, from Nigeria, reported a prevalence rate of 7.5 PMP (12) . 
1.3.4   Prevalence of chronic renal failure in Sudan: 
     Few studies were done in Sudanese children, most of these 
studies were done by individual researcher during short periods of 
time concentrating on one aspect of renal failure .The estimated 
incidence of CRF in Sudan is 70-140 cases per million per year and 
most of the patients are young adults(13). 
      Mohamed A. A. have done a study on the etiology of renal 
failure whether acute or chronic in Sudanese children during the 
period from 1997-1998. Eighty - seven child were studied, 67of them 
having CRF (14) . 
1.4  Etiology of CRF:  
The conditions that lead to chronic kidney failure in children 
can not be easily fixed. Often, the condition will develop so slowly 
that it can pass unnoticed until the kidneys become permanently 
damaged (15).   
    From birth to age 5 years, congenital abnormalities such as 
renal hypoplasia and hereditary diseases are by far the leading causes 
of kidney failure. Between ages 5 and 14 years, hereditary diseases 
continue to be the most common causes, followed closely by 
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glomerular diseases. In the 15 - 19 year olds; glomerular diseases are 
the leading cause and hereditary diseases become rarer(15) (16). 
The North American Pediatric Renal Transplant Cooperative 
Study Group (NAPRTCS) register confirms that different forms of 
obstructive uropathy (including reflux and dysphasia) account for 
almost 50% of the causes of renal failure. 
Other relatively common causes of ESRD in children that are 
rare in adults include hereditary nephritis, infantile polycystic disease, 
cystinosis and uremic medullary cystic disease. Focal 
glomrulosclerosis is the most common glomerulopathy leading to 
CRF in young children, it accounts for 14.8% of all children with 
ESRF(17) . 
      In Sudan Aboud Oi in his study on CRF in Sudan in  a two years 
period ( 1979 - 1981) studied100 patients ,the majority of them were 
males . Glomerulonephritis accounted for 38% of causes of CRF, 
urinary calculi 12%, diabetes mellitus 9%, chronic interstitial nephritis 
7%, cortical necrosis 5%, renal vascular disease 4%, polycystic disease 
3%, obstructive uropathy 2% and the etiology was uncertain in 20 %of 
the patient (18). 
      In 1998 Mohamed A. A. in his study of Sudanese children with 
renal failure found that chronic GN is the predominant cause of CRF 
(52.2%). Urinary calculi accounted for 7.5%, chronic pyelonephritis 
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4.5%, tumor 5% and uncertain causes in 25.3% of the cases. The 
incidence of GN as a cause of CRF is much higher than that in 
American and European reports, but is similar to other reports from 
adults in Sudan (14) . 
     Abdelraheem M. B. in his study of the renal bone disease in 
Sudanese children with CRF found that the cause is uncertain in 
49.1% of cases. Obstructive uropathy and GN were the causes of CRF 
in 15.8% of the patients each (19) . 
1.5 Pathophysiology and Clinical Manifestations of CRF: 
1.5.1 Pathophysiology: 
     Approximately 1 million nephrons are present in each kidney, each 
contributing to the total GFR.   Regardless of the etiology of renal 
injury, with progressive destruction of nephrons, the kidney has an 
innate ability to maintain GFR by hyperfiltration and compensatory 
hypertrophy of the remaining healthy nephrons. However the plasma 
creatinine value will double with a 50% reduction in GFR.  
     The residual nephron hyperfiltration and hypertrophy, although 
beneficial has been hypothesized to represent a major cause of 
progressive renal dysfunction. This is believed to occur because of an 
increased glomerular capillary pressure, which damages the capillaries 
and leads initially to focal and segmental glomerulosclerosis and 
eventually to global glomerulosclerosis (4). 
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1.5.2   Clinical manifestation of progressive renal function loss: 
        In many children chronic renal failure will be the end   result of 
a known progressive renal disease (20). 
       Early in the course of kidney failure, patients may be 
asymptomatic. Laboratory tests can reveal excess serum creatinine, 
excess blood urea nitrogen (BUN), or protein in the urine. The 
creatinine clearance test is a useful measure of the kidney function (21) . 
        Some early non specific symptoms and signs of kidney disease 
are frequent headaches, fatigue and itching .Disease progression is 
associated with an alteration in urination frequency, loss of appetite, 
nausea, vomiting, fatigue and weakness (22) .   Other signs and 
symptoms include decreased mental concentration, darkening of the 
skin and muscle cramps all being features of the uremic syndrome that 
results from building up of excess waste products in the body (23) (24) .  
       On the other hand accumulation of excess fluid in the body will 
result in swelling of the hands and feet and a high blood pressure. In 
addition, acid produced during metabolic processes can accumulate in 
the body, causing metabolic acidosis (23) . 
      The kidneys fail to excrete phosphate, leading to increased 
blood phosphate levels that, in turn cause a decrease in blood calcium 
levels. Low calcium levels can lead to brittle bones (renal 
osteodystrophy) and rarely a life-threatening hypocalcaemia. Of 
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course renal failure can present with other complications such 
anemia. 
      Generally children with CRF present in a different way from that 
of adults. Certain common findings should therefore alert the 
pediatrician to the possibility of chronic renal disease and those 
include anemia, growth failure, hypertension, acidotic breathing and 
renal osteodystrophy (24) . 
 1.6   Complications of CRF:  
          A normocytic normochromic anemia is inevitable in CRF due 
to loss of erythropoietin production and is considered a risk factor for 
early death (25) .   Impaired white cells and platelets functions lead to 
increased susceptibility to infection and easy bruising. 
       Hypocalcaemia is a potentially life threatening complication of 
CRF and results from loss of vitamin D and increased parathyroid 
hormone levels. Hypermagnesemia may also occur. Hyperkalemia is 
the most common immediately life-threatening metabolic 
complication of renal failure and may develop suddenly when GFR is 
severely reduced. An anion gap acidosis results from decreased 
hydrogen ion excretion and may exacerbate hyperkalemia. 
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       Volume overload is a common cardiovascular complication of 
renal failure that occurs when salt and water intake exceeds losses and 
excretion. 
      Growth failure is a major problem for children with CRF. The 
severity of growth failure is related to the age of presentation. Fifty 
percent of children with renal failure starting in infancy have growth 
failure with height of >2SD below the mean height for age in contrast 
to 10% of those with acquired disease. (22) Disturbances of pubertal 
development are commonly encountered in adolescent patients with 
CRF (26). 
     Hypertension is a frequent cause of CKD. Systemic 
hypertension causes direct damage to small blood vessels in the 
nephron. Several trials have demonstrated the benefit of strict blood 
pressure control in slowing the progression of kidney disease. The 
optimal target blood pressure for children with chronic renal failure is 
currently recommended to be below the 90th percentile for age (1) .  
     CRF is associated with specific abnormalities of skeletal 
homeostasis, commonly called renal osteodystrophy (ROD), which if 
not treated appropriately during the critical phases of skeletal growth 
can result in bone deformities and in a disturbed growth pattern. The 
main factors for the development of ROD are disturbances in the 
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calcium phosphate homeostasis, vitamin D and parathyroid hormone 
metabolism as well as alterations in the somatotrophin axis (27) . 
      Pericarditis, serositis, gout, pseudogout, hypothyroidism, 
seizures, fractures, bleeding, gastrointestinal mucosal ulcerations and 
lipid disorders are all known complications of CRF (28) . 
1.7    Predictive Factors for Progression of Renal Disease: 
      Both renal and non renal predictive factors may take place 
and/or facilitate the progression to renal failure. Some of the       non-
renal predisposing factors both in children and adults are genetic 
predisposition, low birth weight, hyperlipidemia, obesity, 
cardiovascular diseases, and low economic and educational status. 
     Renal predictive factors for progression to renal failure are low 
baseline creatinine clearance (<50 ml/min/1.73 m2), focal segmental 
glomerulosclerosis (FSGS) at presentation, low hematocrit, 
hypoalbuminemia, hypocalcaemia, hyperphosphatemia and 
hyperparathyroidism (29).  In another study, GFR under 30ml/min 
and severe proteinuria were reported to be independent predictors of 
progression to ESRF in children (30) .     
1.8     Management of CRF:  
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      Treatment of CRF focuses on controlling the symptoms, 
slowing the progression of the disease and minimizing and treating 
complications (24).   The main parameters of treatment are: 
(1) Conservative treatment (dietary modification and medications to 
control complications and associated conditions).  
(2)    Renal replacement therapy (dialysis or transplantation). 
1.8.1    Diet in CRF: 
       It is not justified to prescribe special diet to children early in the 
course of CRF, but the composition of their nutrition should follow 
the general concept of an optimal mixed diet (23) to ensure adequate 
energy intake, maintain optimal nutrition and   avoid malnutrition (24) 
. 
1.8.2    Treatment of anemia: 
      The treatment of anemia in patients with CRF can help in 
reducing cardiac complications which are the major cause of death in 
patients with ESRD (31). The most effective treatment is with 
subcutaneous erythropoietin (32) . 
1.8.3    Treatment of hypertension:  
      Hypertension in patients with renal disease is best treated with a 
combination of Angiotensin converting enzyme inhibitors (ACEI) 
and angiotensin-II receptor antagonists. Both lower intraglomerular 
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pressure and reduce proteinuria. Angiotensin-II receptor antagonists 
can also reduce the occurrence of kidney failure (33)(34) . 
1.8.4    Prevention of renal bone disease:       
      The first step is to limit phosphate intake. Simple measures 
include educating patients to avoid foods high in phosphates 
particularly cola-based soft drinks, nuts, seeds and peanut butter. The 
next step is to use a calcium-based phosphate binder with meals (e.g. 
Tums, calcium carbonate, 500–1500 mg with each meal (30). 
1.8.5    Maintenance of acid- base balance: 
     Renal failure generally does not lead to serious acidosis until the 
GFR falls to <0.33 ml/s. Current recommendations are to start 
treatment when the pH level falls below 7.2 or the serum bicarbonate 
falls below 15 mmol/l. Sodium citrate, sodium bicarbonate or 
calcium carbonate is given orally until the serum bicarbonate level is 
>20 mmol/l. The choice of the agent should be determined by 
whether one needs to use calcium carbonate as a phosphate binder 
(32)(16) . 
1.8.6    Renal Replacement Therapy:    
     When renal failure is severe and about 90% of renal function is 
lost, the patient requires a form of renal replacement therapy to 
survive:  a renal transplant or dialysis (35) . 
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     Dialysis is a process that cleans and filters the blood, removing 
harmful wastes and excess salt and fluids by passing blood across a 
semipermeable membrane (36)(37) .   Dialysis can control blood pressure 
and help maintain a balance of electrolytes, including potassium, 
sodium and chloride .There are 2 main types of dialysis: hemodialysis 
and peritoneal dialysis.  
     The hemodialysis machine is connected to a special filter called 
a dialyzer. During hemodialysis blood is carried to the dialyzer where 
wastes and excess fluids are removed (37) .  The cleansed blood is 
carried back to the body. Hemodialysis is usually performed 3 times 
weekly, with each treatment lasting 2 to 4 hours.  
    Peritoneal dialysis uses the peritoneal membrane, the lining of the 
abdomen, to remove excess water, wastes, and chemicals from the 
body(37) .  A dialysate passes through the abdomen via a surgically 
placed catheter. Fluid, wastes, and chemicals pass from capillaries in 
the peritoneal membrane into the dialysate. After several hours, the 
waste-carrying dialysate is drained from the abdomen. There are 3 
types of peritoneal dialysis:  
1. Continuous ambulatory peritoneal dialysis (CAPD).  
2. Continuous cyclic peritoneal dialysis (CCPD).  
3. Intermittent peritoneal dialysis (IPD). 
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    CAPD is the most common type the dialysate passes from a 
plastic bag through a catheter and into the abdomen (37) .  After 4 to 6 
hours the solution is drained back into the bag and replaced with fresh 
solution. The solution is usually changed 4 times a day. CCPD is like 
CAPD, except that a machine is used to fill and drain the dialysate 
through the catheter.  This procedure is performed nightly during 
sleep for 10 to 12 hours. Intermittent peritoneal dialysis uses a 
machine, much like CCPD, to add and drain the dialysate. Each 
session may last for up to 24 hours. Intermittent peritoneal dialysis 
treatments are usually performed in a hospital for a total of 36 to 42 
hours weekly (37) . 
1.9      Lipids: 
1.9.1    Definition of lipids: 
Lipids include fats, oils, steroids, wax and related compound. 
They are a heterogeneous group of substances related more by their 
physical rather than by their chemical properties. These shared 
properties are: 
(1) The relative insolubility in water.  
(2) Their solubility in non-polar solvent such as ether, 
chloroform and benzene (38). 
1.9.2     Biomedical importance of lipids:  
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    In the body fat serves as an efficient source of energy both 
directly and potentially when stored in adipose tissues. It is also 
important in thermal regulation acting as a thermal insulator in the 
subcutaneous tissues.  Non-polar lipids on the other hand act as an 
electrical insulator allowing rapid propagation of depolarization in the 
demyelinated nerves.  
   Another important function of lipids is the role of lipoproteins as an 
important cellular constituent and a transporter of lipids in the blood 
(38). 
1.9.3    Classification of lipid: 
      Lipids are generally classified into 3 main groups these are: 
(1)  Simple lipids which are esters of fatty acids (FA) with various 
alcohols, and include:   
-  Fats: Esters of FA with glycerol, when in the liquid state 
are known as oil. 
- Waxes: Esters of FA with higher molecular weight 
monohydric alcohols. 
(2) Complex lipids which are esters of FA containing other 
groups in addition to alcohol and FA .members of this 
group include:  
- Phospholipids which contain a phosphoric acid residue. 
They are the main lipid constituents of cell membrane.  
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- Glycolipids (glycosphingolipids) they are important in 
nerve tissue and contain sphingosine and carbohydrate in 
addition to FA and alcohol. 
- Lipoproteins and other complex lipids such as 
aminolipids and Sulpholipids.  (38) (39) 
(3)   Precursors and derived lipids:  
     These include fatty acid, glycerol, steroid and fatty aldehydes.   
1.9.4    Human blood plasma lipids: 
       Lipids of the blood plasma in human are transported as  
lipoproteins.  Four major classes of lipids are found in the plasma 
lipoproteins  theses are triglyceride (TG) 45%, total phospholipids   
35%  total cholesterol (TC) 15% and free fatty acid (FFA)< 5% (37) . 
1.9.4.1 Cholesterol: 
     Cholesterol is probably the best known steroid because of its 
association with atherosclerosis. However it is also important, being 
the precursor of a large number of equally important steroids which 
include bile acids, vitamin D and sex hormones (40) (41) . 
     Cholesterol is present in tissues and in plasma lipoprotein as 
free cholesterol or combined with long-chain fatty acid as cholesterol 
ester. It is synthesized in many tissues from acyl–COA and is 
eliminated from the body in the bile as cholesterol or bile salts (37)(42) . 
1.9.4.2    Triglycerides:   
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     Triglycerides are the ideal means of energy storage in fat cells, 
where they also act as “cushions” and provide a layer of insulation (43)  
. 
1.9.4.3  Fatty Acids (FA): 
      Fatty acids are released by the effect of the enzyme lipoprotein 
lipase from glycerol to which they are bound in the stored 
triglycerides. Released free fatty acids bind to serum albumin and are 
used as sources of energy for muscle activity. Then they are taken up 
by the liver or re-synthesized back in to triglycerides (43) . 
1.9.5    Definition of lipoproteins: 
   Lipoproteins are complexes of non-polar lipids (TG and cholesterol 
ester), amphipathic lipids (phospholipids and cholesterol) and  a 
protein. The main function of these complexes is to facilitate  the 
transportation of fats absorbed from the intestine and lipids 
synthesized by the liver and adipose  tissue between the various 
tissues and organs for utilization or storage (45). 
              Lipoproteins can be separated by ultracentrifugation or electrophoresis, and
lipoprotein (LDL), intermediate density lipoprotein (IDL), high 
density lipoprotein (HDL) and a fifth type named chylomicorn in the 
post abortive period (47) . 
1.9.5.1  VLDL :  ( pre-B-lipoprotein) :   
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     VLDL is mostly derived from the liver for export of TG to extra 
hepatic tissue. In plasma it is converted to IDL and LDL.  
Triglyceride is the main lipid in VLDL. 
1.9.5.2 LDL (B-lipoprotein):    
     Represents the final storage of VLDL and is the major 
transporter of cholesterol in the plasma (47).  Cholesterol is the main 
lipid of this group. 
1.9.5.3 HDL: (-Lipoprotein):  
    Is the transporter of cholesterol from tissue to liver, and has 
phospholipids as the predominant lipid (48) . 
 
1.9.6    Apolipoproteins: 
     Apolipoproteins are the protein components of lipoproteins.  
They maintain the structural integrity of lipoprotein, facilitate their 
secretion, co-activate enzyme reactions necessary for lipoprotein 
processing and facilitate receptor-mediated uptake of lipoproteins and 
remnants (33)(49) . 
 
Table: Apolipoproteins of human plasma lipoproteins 
Apolipoprotein Lipoprotein Apolipoprotein Lipoprotein 
Apo A -I HDL Apo B48 Chylomicrons 
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Apo A-II ,chylomicrons Apo- CI 
Apo A-IV Chylomicrons Apo C-II 
Apo B-100 LDL,VLDL,IDL Apo C III 
Apo D HDL Apo E 
VLDL,HDL 
chylomicrons 
       
1.9.7     Dyslipidemia:  
    Dyslipidemia is a primary risk factor for cardiovascular disease 
and a common complication of progressive kidney disease.  Most 
patients with chronic kidney disease have an abnormal lipid panel 
that increases their risk for atherogenesis. Dyslipidemia contributes to 
cardiovascular mortality, which is 10 to 20 times higher in dialysis 
patients than in the normal population even after adjustments are 
made for age and sex (50)(51). 
1.9.7.1 Patterns of Dyslipidemias in CRF : 
    The most noticeable lipid abnormality in chronic kidney disease 
is an elevated triglyceride level, possibly because of an increased 
production or defective clearance (23), (24) .   Patients with chronic 
kidney disease also have an elevated levels of cholesterol mainly due 
to enhanced biosynthesis(52).  
    The characteristic pattern is an accumulation of partially 
catabolized apoB- containing, triglyceride –rich, particles of the 
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VLDL and IDL class leading to hypertriglyceridemia(3) .  The 
concentration of HDL is decreased with reduced relative concentration 
of free and esterified cholesterol and increased triglyceride content. 
The concentration of the HDL2 sub fraction is low whilst HDL3 is 
normal although the concentration of LDL are not generally 
increased (3).  There is a predominance of small, dense particles which 
are particularly susceptible to oxidation ,bind weakly to LDL 
receptors and are cleared slowly from the plasma. These small 
particles are thought to be more atherogenic than larger LDL 
subfraction (53) .  
     The apoprotein composition of particles is altered with an early 
and marked increase in apoCII in VLDL and LDL and decrease in 
apoA1 content of HDL these abnormalities, coupled with change in 
the concentration of the particles, lead to a characteristic decrease in 
apoA1: CIII ratio, which is considered to be the hallmark of uremic 
dyslipidemia. This decrease is detectable when the glomerular 
filtration rate is only moderately reduced and plasma triglyceride is 
still normal   (54) . 
1.9.7.2    CRF-associated hypertriglyceridemia: 
      High prevalence of hypertriglyceridemia (HTG) in chronic 
renal failure (CRF) was reported for the first time more then 30 years 
ago and since then it was claimed a metabolic consequence of the 
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disease . HTG is important at least of two reasons: it is partially 
responsible for the accelerated atherosclerosis found in patients with 
CRF and moreover, it is presumed to stimulate the progression of 
CRF (55) . 
  1.9.7.3    CRF-associated cholesterol abnormalities: 
      The high level of cholesterol in patients with CRF is due to an 
elevated ratio of low-density lipoprotein (LDL) cholesterol to high-
density lipoprotein (HDL) cholesterol. LDL cholesterols are pro-
atherogenic, and levels are slightly elevated in patients with chronic 
kidney disease. Levels of oxidized LDL cholesterol are also elevated. 
These cholesterols activate proinflammatory pathways, thereby 
promoting atherogenesis and endothelial dysfunction. HDL 
cholesterol levels are decreased, indicating loss of anti-atherogenic 
effect (56)(34) . 
1.9.7.4 Mechanisms of dyslipidemias in patients with chronic renal 
insufficiency:  
     The mechanisms behind the dyslipoproteinemia of uremia are 
not fully elucidated. . Hypertriglyceridemia and increased lipoprotein 
remnants in renal insufficiency have been attributed to impaired 
lipoprotein lipase (LPL) and hepatic triglyceride lipase (HTGL) 
activities(57)(58) . 
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     Regarding the mechanism behind the decrease in LPL activity 
in uremia, three theories prevail, all of them supported by clinical or 
experimental findings: 
(1) Reduced enzyme synthesis by the parenchyma cell; 
(2) Circulating inhibitor(s) against the enzyme activity and  
(3) Heparin- induced depletion of the functional enzyme pool 
(in   hemodialysis patients). 
      Receptor-mediated uptake of lipoproteins is also disturbed and 
there is an evidence of malfunction of LDL (B-100/E) receptor in CRI 
patients and a significantly reduced catabolic rate of LDL particle. In 
addition to a disturbance in LDL-receptor function, there are 
impairments in the receptor ligand characteristics of uremic LDL(59) . 
 
1.10 Recent Advances in Factors That Alter Lipid 
Metabolism in Chronic Renal Failure:      
      The presence of apo B-48 in serum VLDL and the high serum 
apo A-IV concentrations indicate a greater than normal contribution 
of alimentary remnant particles to the hypertriglyceridemia of uremic 
patients: 
1. The presence of apo E and C in triglyceride-enriched serum 
LDL, together with the triglyceride enrichment of all 
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lipoproteins, probably stems from a deficiency of lipoprotein 
lipase (LPL) and hepatic lipase (HL) activity, 
2. The decreased ratio of serum apo C-II/C-III in VLDL is at least 
in part responsible for the depressed activity of LPL,  
3. The accumulation of lipoprotein particles with distorted 
apoprotein and lipid patterns (particularly beta-VLDL with 
enrichment in cholesterol) could be associated with an 
increased atherogenesis because a recent study has 
demonstrated a stronassociation between raised serum IDL and 
VLDL concentrations and the degree of coronary 
atherosclerosis . 
4. The increased apo E content of VLDL and HDL in uremic 
patients could particularly point to a disturbed cholesterol 
metabolism because such lipoproteins could interact with LDL 
at apo B, E receptors, 
5. The decrease in serum HDL-cholesterol has been shown to be 
strongly associated with atheromatous vascular disease, and this 
could also true  for uremic patients; however, it is probable that 
low serum HDL-cholesterol together with a diminished 
capacity to form cholesterol-rich, apo E containing HDL 
represents a decrease in the antiatherogenic defense of the 
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organism rather than an increased atherogenic potential (3) (60) 
(61)(62) (63). 
 
1.11 Effect of Renal Replacement Therapy on 
Hyperlipidemia:   
1.11.1 Hyperlipidemia in children on dialysis: 
      Hyperlipidemia is one of the major complications of peritoneal 
dialysis (PD). Interesting phenomenon is observed in children on PD: 
the younger the patient, the higher the serum lipid levels.   Several 
hypotheses have been proposed regarding the etiology of the 
hyperlipidemia in continuous ambulatory peritoneal dialysis (CAPD) 
patients, including reduced catabolic function. Protein loss via the 
dialysate, hypoalbuminemia, and glucose absorption from dialysate 
(64). 
      Dyslipidemia in CRF is not corrected by dialysis, although the 
lipoprotein pattern may be modified. Raised triglyceride are found in 
between 30% to 70%  of the patients undergonging dialysis, 
hypercholestremia is less commonly observed, is more likely to be 
present in patients receiving continuous ambulatory peritoneal 
dialysis (CAPD ) than those receiving haemodialysis, probably 
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because of glucose absorption from the dailysate  and peritoneal 
protein losses (5-15gm/day )(65) . 
1.11.2      Renal transplantation and dyslipidemia: 
      Dyslipidemia may worsen after renal transplant and the pattern 
of abnormality usually change. Current immunosuppressive regimen 
combining cyclosporine and corticosteroid have an important 
contributory role  (66) 
      Two years after transplantation, increased total LDL and HDL 
cholesterol, decreased VLDL cholesterol and normal VLDL 
triglycerides have been reported in stable patient receiving 
cyclosporine, azathioprine and prednisolone (67) . 
  
1.12     Screening of Hyperlipidemia: 
      The National Cholesterol Education Program (NCEP) Pediatric 
Panel recommended a policy of selective screening of hyperlipidemia 
in children. This selective screening program is recommended for 
children and adolescents 2years of age or more with: 
(1) Positive family history of premature cardiovascular disease in 
an expanded first-degree pedigree (i.e., to include not only 
parents and siblings, but also aunts, uncles and 
grandparents). 
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(2) A history of parental hypercholesterolemia (> 240mg/dl). 
(3) Multiple risk factors for CHD (such as smoking or obesity) 
and whose family history cannot be ascertained.  
     The NCEP recommends screening with fasting lipid profile in 
those with family history of premature cardiovascular disease, non 
fasting total cholesterol for those with parental hypercholesterolemia 
and periodic total blood cholesterol for those with several risk factors 
at the discretion of the physician  (68) . 
      According to the NCEP, calculated very low density lipoprotein 
(VLDL) levels are sufficiently accurate; VLDL is calculated as total 
triglycerides divided by 5. The NCEP recommends direct 
measurement of LDL cholesterol in persons with triglyceride levels 
greater than 400 mg/dl  (69) . 
    The National Cholesterol Education Program (NCEP) 
determined the different plasma levels in children in mg/as shown in 
table below (34). 
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Children < 20 
years 
Desirable  
Level 
Border line 
level 
Elevated  
Level 
TC < 170 170 – 199 > 200 
LDL.C < 110 110 – 129 > 130 
HDL.C > 45 35 – 45 Low when < 35 
TG < 125  > 125 
 
  1.13    Treatment of Dyslipidemia: 
     Although no large randomized controlled trials have studied the 
effects of lipid reduction on the progression of kidney disease, animal 
models suggest that dyslipidemia worsens kidney function. A recent 
meta-analysis 13 of 32 small studies showed that lipid reduction 
preserves GFR and reduces proteinuria. The most recent guidelines 
from the NKF- K/DOQI recommend treating dyslipidemia 
aggressively in patients with chronic kidney disease (70) .  
1.13.1   Assessment of Dyslipidemia: 
According to the NKF K/DOQI33 
? All adults and adolescents with CKD should be evaluated 
for dyslipidemias. For adults and adolescents with CKD, the 
assessment of dyslipidemias should include a complete fasting 
 30
lipid profile with total cholesterol, LDL, HDL, and 
triglycerides. 
? For adults and adolescents with Stage 5 CKD, dyslipidemia 
should be evaluated upon presentation (when the patient is 
stable) at 2-3 months after a change in treatment or other 
conditions known to cause dyslipidemias; and at least 
annually thereafter. 
? For adults and adolescents with Stage 5 CKD, a complete 
lipid profile should be measured after an overnight fasting 
whenever possible.Hemodialysis patients should have lipid 
profiles measured either before dialysis, or on days not 
receiving dialysis. 
? For adolescents with Stage 5 CKD and fasting triglycerides 
>500 mg/dl (>5.65 mmol/l) that cannot be corrected by 
removing an underlying cause, treatment with therapeutic 
lifestyle changes (TLC) should be considered.  
? For adolescents with Stage 5 CKD and LDL >130 mg/dl 
(>3.36 mmol/l), treatment should be considered to reduce 
LDL to < 130mg/dl(>3.36mmol/L). 
? For adolescents with Stage 5 CKD and LDL < 130 mg/dl 
(>3.36 mmol/L), fasting triglycerides > 200 mg/dl (>2.26 
mmol/L), and non-HDL cholesterol (total cholesterol minus 
 31
HDL) >160 mg/dl (>4.14 mmol/L), treatment should be 
considered to reduce non-HDL cholesterol to < 160 mg/dl 
(<4.14 mmol) (71) . 
1.13.2 Approach for treating high LDL and high non-LDL 
cholesterol: 
      For LDL levels of130-159 mg/dl (3.36-4.11 mmol/L), TLC 
should be used first. If after 6 months of TLC, LDL is > 130 mg/dl 
(>3.36 mmol/L), then consider pharmacological management. If 
LDL is >160 mg/dl (> 4.14 mmol/L), then consider starting 
atorvastatin at the same time as TLC. 
1.13.2.1    Therapeutic lifestyle changes (TLC) : 
      Dietary fat restriction is safe in children in particular; there have 
been no adverse effects on growth and development or nutrition.      
However, TLC should be used judiciously, or not at all, in children 
who are malnourished. If TLC has failed after 6 months, and 
potential secondary causes of dyslipidemia have been ruled out, drug 
therapy should be considered (71) . 
 1.13.2.2    Drug therapy: 
      There are few studies examining drug treatment of dyslipidemia in 
children with CKD. However, a limited number of small randomized 
controlled trials in children and adolescents from the general 
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population have found that statins are safe and effective in lowering 
LDL(72) . 
     Statins are clearly beneficial in the renal transplant recipient who is at 
high risk of developing hyperlipidemia and accelerated atherosclerosis. The 
immunomodulating, vasodilatory and anti-proliferative effects of the statins, at 
least as demonstrated in vitro, may be of additional benefit in reducing the risk 
of rejection and chronic allograft nephropathy, thereby prolonging graft 
survival, although the data in this regard are not consistent (73) .                
       Currently, the only statin approved by the United States Food and 
Drug Administration (USFDA) for use in children and adolescents is 
atorvastatin. Bile acid sequestrants appear to be safe and effective in 
improving dyslipidemias in children. Bile acid–binding resins block bile 
reabsorption from the gut, resulting in bile excretion in the stool. 
Compensatory hepatocytes bile synthesis increases, which increases hepatocytes 
LDL-R expression. Increased LDL-R expression on the hepatocytes surface 
increases LDL clearance, reducing LDL-C concentrations(74) . 
 
     Cholestyramine is approved for use in children by the USFDA. 
Although bile acid resins are safe in children of all ages, adherence to 
therapy is often poor due to the high incidence of adverse effects. 
Adverse effects are common and include constipation, abdominal 
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discomfort, nausea, flatulence, vomiting, diarrhea, heartburn, 
anorexia, and indigestion (75) . 
      Niacin is the second-line drug that the NCEP recommends for 
the treatment of elevated LDL-C levels in children. Niacin appears to 
decrease lipoprotein production and increase lipoprotein  clearance 
(75). Initiation at a low dose is followed by up titration to a daily dose 
of 2 to 6 g/d. adverse effects, predominantly flushing, are very 
common. Several serious adverse effects are at concern, including 
glucose intolerance, myopathy, hyperuricemia, and fulminant hepatic 
failure (76) . 
1.14  Studies Done on Hyperlipidemia in CRF: 
1.14.1 Studies done in children: 
    Mohamed Ragab and Amany Ragab in Egypt 2004, studied 
lipid profile in children with chronic renal failure on conservative 
therapy and with regular hemodialysis, they found that abnormalities 
in basic lipid profile were more frequently detected in children with 
chronic kidney disease under regular hemodialysis than those on 
conservative therapy only. Triglycerides were found to be elevated in 
53.5% and total cholesterol in 21.4% in the conservatively managed 
group. However, in haemodialyzed group hypertriglyceridemia and 
lower HDL were detected in 77 % and 90.9 % respectively. They 
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recommended evaluating dyslipidemia in these children more than 
general population, and early intervention might be of protective 
value for the cardiovascular system(77). 
In 1993  at University of Heidelberg, Germany ,U Querfeld and  
others  studied Disturbances of lipid metabolism in children with 
chronic renal failure they stated that inaddition to the characteristic 
uremic hypertriglyceridemia and lower HDL in children ,serum levels 
of total cholesterol ,VLDL ,LDL ,and apolipoprotein B are frequently 
elevated in children with chronic renal failure (78) . 
? U Querfeld also studied Lipoprotein(a) serum levels and 
apolipoprotein(a) types in children with  chronic renal disease 136 
patients were studied in the age group .8 to 24.7 years  .They  
conclude that increased Lipoprotein(a) serum levels are found in 
13%-42% of young patients with chronic renal disease, possibly 
predisposing them to an increased risk for atherosclerosis and 
thrombosis (79) . 
? In 1984 K Asayama, and others studied Lipid profiles and lipase 
activities in nine children with kidney transplants, nine 
hemodialyzed children and 18 conservatively treated children with 
chronic renal failure .they found All groups of patients had 
hypertriglyceridemia (80).  
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? In 1981, ZL Papadopoulou, studied total serum cholesterol, 
phospholipids and triglyceride levels and lipoprotein fractionation,   
in a group of 31 non nephrotic children with various levels of renal 
function and on hemodialysis. A significant (P less than 0.05) 
increase in triglyceride levels was observed in children with GFR 
of 10 to 40 ml/min/1.73 m2, and those on  maintenance 
hemodialysis with GFR of 0 to 5 ml/min/1.73 m2. There were no 
significant differences observed in the beta lipoproteins (LDL). 
However, the alpha lipoproteins (HDL) decreased significantly in 
patients whose GFR was below 40 ml/min/1.73 m2 as well as 
patients on maintenance hemodialysis(81) . 
?  In 1976 Hyperlipidemia after renal transplantation in children Iis 
studied by L. F. Saldanha. A cross-sectional survey of 32 children 
who received renal allografts was undertaken to evaluate lipid 
profiles in a pediatric transplant population. Ages ranged from 8 to 
18 years, and serum creatinine concentrations varied from 0.5 to 
5.6 mg/100 ml (mean, 1.4 mg/100 ml). Fifty percent of patients 
showed an abnormal lipoprotein electrophoresis, The data 
suggested that increasing levels of cholesterol and triglyceride are 
associated with higher corticosteroid dosages. Lipid abnormalities 
following renal transplantation in children are similar to those 
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described in adults, and may contribute to morbidity in the years 
following successful renal transplantation(82) .  
1.14.1.1 Studies done in adults: 1     
 Studies done in adults show that : 
? In Kuwait June 2004, Al-Rashidi M and others evaluated 
changes in blood lipoproteins and apolipoproteins after dialysis 
in ESRD patients.  They found that levels of atherogenic 
lipoproteins increase post-dialysis in diabetic and non-diabetic 
patients with ESRD and the changing levels of these 
lipoproteins correlate significantly with corresponding changes 
in levels of apolipoprotein (83) . 
? Nelva T. and others ,1n 2001 determined the plasma and 
erythrocyte lipid profile in patients with chronic renal failure (CRF) 
along 30 months under hemodialysis  ; Triglyceride levels were 
increased in the plasma and in erythrocyte membranes of CRF 
patients compared to healthy subjects. The lipid composition 
abnormalities persisted after 18 months and they became more 
notorious after 30 months. They concluded that CRF patients of 
regular hemodialysis had a gradual deterioration in the fatty acid and 
triglyceride abnormalities, a finding that might be relevant to the risk 
of cardiovascular disease in this setting (84) . 
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? Avram MM and his colleagues studied in 1999 the uremic 
dyslipidemia as a cross-sectional and longitudinal study . They found 
that CAPD patients have more atherogenic lipoprotein profiles than 
HD patients (85) . 
?  Shah B, Nair S,  in 1994, studied Dyslipidemia in patients with 
chronic renal failure and in renal transplant patients.The study 
included 4 groups; Group I: control subjects (n = 9, age = 30 +/- 5 
yrs), Group II: CRF patients on conservative treatment (n = 9, age = 
49 +/- 17 yrs), Group III: ESRD patients on HD for at least 3 months 
(n = 19, age = 53 +/- 9 yrs), Group IV: 3 months post-renal transplant 
patients (n = 9, age 31 +/- 11 yrs).they found that : 1) significant 
hypertriglyceridemia does develop in a majority of CRF patients. The 
abnormality probably improves with dialysis treatment and renal 
transplantation. 2) A lower Apo A1/Apo B ratio in CRF patients may 
account for higher risk of atherosclerosis. 3) Fish oil rich in 
polyunsaturated fatty acids improves hypertriglyceridemia of CRF (86) . 
?  In 1983, Ravichandran RR, and others studied the behavior of 
various lipid fractions in C.R.F. patients. Forty patients of chronic 
renal failure who were either admitted or being followed up in the 
nephrology department of the K.E.M. Hospital, Bombay were 
studied. Twenty normal persons were included as healthy controls 
(Group I). Out of the 40 patients, 20 were undialysed patients, being 
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managed conservatively (Group II) and the other 20 were on regular 
hemodialysis (Group III). The 3 groups of patients studied were 
comparable as regards to the age and sex distribution. The male to 
female ratio in the 3 groups was 2.3:1. Their ages varied between 16 
and 55 years, they found that levels of fasting free fatty acids were 
significantly lower in the dialyzed group of patients (p < 0.05). The 
fasting serum triglycerides were significantly elevated in both groups 
of renal failure patients (p < 0.02) (87) . 
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Justification 
 
 
 
 
 
1. Hyperlipidemia is a common problem in patients with chronic 
renal failure.                                                                                                
2. Hyperlipidemia is important factor in progression of chronic 
renal failure . 
3. Hyperlipidemia associated with increased risk of cardiovascular 
disease which is the leading cause of morbidity and mortality in 
patients with end-stage renal disease (ESRD). Both in dialysis 
(hemodialysis, continuous ambulatory peritoneal  dialysis) and 
in transplanted  patients .                                                                                          
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OBJECTIVES 
 
 
 
To determine the pattern and prevalence of lipid profiles on 
chronic renal failure patients on: 
? Conservative treatment .  
? End stage renal disease (ESRD) . 
? Regular dialysis ; continues ambulatory  peritoneal dialysis 
(CAPD) and  haemodialysis (HD) . 
? Post kidney transplanted children  
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Chapter Two 
2- Material and Methods 
2.1  Study Design :   
               Cross sectional hospital based study. 
2.2 Study Area :   
The study was conducted at: 
?    Dr. Salma kidney, dialysis and transplantation center. 
?    Dialysis unit Soba University hospital. 
?    Dialysis unit Khartoum Teaching Hospital. 
?     Khartoum North Hospital Renal Center. 
2.3  Study Period:     
       The data was collected within six months from December 2006 
to May 2007.  
Time frame 
 
 
 
 
 
 
 
 
 
 
2.4    Case Definitions:    
6th 5th 4th3rd2nd1st
 Final report 
 Draft report 
      Data entery&analysis 
      Data collection 
 Preparation 
Time per MonthsActivity 
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Chronic renal failure:     
Defined as an irreversible and progressive reduction in the GFR 
to below 25 % of normal level for at least three months.  ESRF is an 
irreversible and progressive reduction in the GFR to below 10 %. 
2.5  Sample Size and Sampling Technique:  
2.5.1 Study population: -  
   The study population includes four groups: 
                  Group I :   Control . 
                  Group II:  CRF on conservative management. 
                 Group III :  CRF on chronic dialysis .  
                  Group IV:  Transplant   patient. 
2.5.2 Inclusion criteria:  
    All children below 18 years of age with a diagnosis of CRF and      
           maintained on: 
? Chronic regular  dialysis( hemodialysis or  CAPD)  
? Conservatively managed  
? Renal transplanted patient 
          after taking verbal consent from parents or caregiver . 
 
2.5.3      Exclusion criteria:                                                  
o Non-consenting caretakers or the patients.  
o Cases of CRF due to nephrotic syndrome 
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 2.5 .4   Sample size: 
      Since the international prevalence of chronic renal failure is very 
small and there is no prevalence from a near by country a total 
coverage sample has been taken. This included all children presenting 
to the above mentioned hospitals and fulfilling the inclusion criteria, 
the total number was 58 patients during the period of the study.   
    2.6  Study Tools:   
? Questionnaire. 
? History and growth assessment. 
? Blood pressure assessment.  
? Lab investigation 
2.7 Study Technique: - 
? Consent was obtained from all parents and children included in 
this study.  
? The mothers were interviewed through the questionnaire by the 
author. 
? Questionnaire for data collection was divided into four sections: 
? First section contained  personal history . 
? Second section contained the cause of CRF , duration of illness 
and determination of the stage of renal failure according to 
GFR . 
? Third section included Growth parameters according to the 
NCHS were plotted to all participants. Arterial blood pressure 
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was measured in the setting position using appropriate cuffs and 
NHLBI charts. 
? Fourth section included the type of management each patient 
received and the duration of management  
? .GFR will be calculated according to the  Schwartz Formula : 
              GFR (mL/min/1.73 m2) = k (Height) / Serum Creatinine 
? k = Constant which differs according to  age : 
k = 0.45 in infants. 
k = 0.55 in Children to 13 years  
k = 0.65 in Adolescent males (Not females because of the 
presumed increase in male muscle mass. The constant remains .55 
for females.)  
? Height in cm  
? Serum Creatinine in mg/ dl 
? Fasting blood sample (at least 8 hrs ) was drawn by 
venipuncture in a heparinized container and centrifuged  to 
separate the plasma .The level of triacylglyceride , total 
cholesterol and HDL was measured using specified reagents 
and a spectrophotometer .  
? VLDL was calculated according to the equation ; 
triacylglyceride level/5=VLDL. 
? then LDL was calculated from the equation: 
 45
  (Total cholesterol –HDL) + VLDL =LDL 
              2.8 Data Management and Statistics: - 
? Data was collected and a master sheet was performed. The data 
was analyzed using statistical package of social sciences SPSS 
version 11.  
? Anthropometric measurements indices were calculated with Epi 
Info, Version 6.04b (Centers for Disease Control and 
Prevention, Atlanta, Ga), based on National Center for Health 
Statistics data and accepted as international standards. Body 
mass index (BMI) was calculated. BMI for age percentile cutoff 
values were used to classify children as either underweight (< 
5th percentile), healthy weight (5th – 84th percentiles), at risk 
for overweight (85th–94th percentiles) or overweight ( 95th 
percentile).  BMI for age Z score cutoff values were used to 
classify children as either normal (> -1 SD), Mild thinness ((-2) 
– (-1) SD), Moderate thinness ((-3) – (-2) SD) or Sever thinness 
(< (-3) SD), these measures provide a simple numeric measure 
of a child's "fatness" or "thinness". 
? Significance testing of difference between proportions was 
conducted using the Chi-square test were applicable, adjusted 
by Pearson's or Fisher's exact test, depending on the number of 
 46
observations, with a value corresponding to p <0.05 for 
significance unless otherwise stated.  
? Results are expressed as mean and standard deviation. The 
significance of difference between two mean values among 
cases and control group were determined by the Student 
independent t test, or ANOVA if we compare more than two 
means with p<0.05 considered significant. 
? Pearson correlation coefficient was used to measure the 
association between continuous data. Correlation coefficients 
(r) range in value from -1 (a perfect negative relationship) and 
+1 (a perfect positive relationship) A value of 0 indicates no 
linear relationship. P value of <0.05 were considered 
significant. This test will not provide a cause -effect relationship. 
?  Statistical analysis was performed by SPSS Computer program.  
Pearson , chi –square, Yate’s correction, and Fisher’s Exact 
tests were used when indicated.  
 
 2.9 Ethical Considerations: 
 
  
- Informed verbal consent from patient and parents will be 
obtained. 
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- A letter will be issued for each unit which takes care of the 
patients explaining the project and ask for their kind 
acceptance and participation. 
            
2.10      Research  Team:  
? Author to  select cases (completes the questionnaire, conduct full  
clinical examination, do anthropometric measurement and  collect 
blood samples). 
? One Lab technician.    
?  One Statistician                                                                                              
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Chapter three 
Results  
 
    During the 6 months of the study period a total of 58 children 
with chronic renal failure were included. Twenty eight normal 
children were included as healthy controls (Group I). Out of the 58 
patients, 18 were on conservative treatment (Group II), 28 were on 
chronic dialysis (Group III). Out of the 28 patients on chronic 
dialysis 17patient were in haemodialysis (HD), and 11were on 
continuous ambulatory peritoneal dialysis (CAPD) and 12 patients 
had kidney transplantation (Group VI) (figure1). 
3.1 Socio-demographic characteristic of the study group: 
3.1.1 Age distribution:  
      The mean age of the study group was found to be11.37 ± 4.2 
years. Most of them 28 (48.3%) were found to be older than 12 
year of age (figure 2). 
3.1.2 Gender distribution: 
     There was obvious male predominance; 36 patients (62.1%) 
were male and 22 (37.9%) were females giving the male to female 
ratio of 1.6:1 (figure 3). 
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3.1.3 Distribution of patients according to residence: 
      The majority 39 (67%) patients were from Khartoum state. The 
remaining 19 (32.7%) patients reside in other states (figure 4). 
3.1.4 Distribution of patients according to origin: 
     Considering the origin of our patients, it was found that most of 
them were from Northern accounting for 25 (43.1%) ,from West we 
had  21(36.2%), from the Central region 11 (19%) and only one 
from Eastern (1.7%) while there was no patient from the Southern 
tribe (figure 5). 
3 1.5 Distribution of patients according to Ethnicity: 
       Thirty four patients (58.6%) were from Arab ethnic 
background, 13 (22.4%) were Afro-Arab and the remaining 
11(19%) patients from African ethnicity (figure 6). 
 3.2 Etiologies of renal failure in study group:  
      The cause of renal failure was uncertain in most of our children 
(n=26 patients, 44.83%). Obstructive uropathy was detected in16 
patients (27.5%) glomerulonephritis was responsible for CRF in 9 
patients (15.52%), while 4 patients (6.90%) had hereditary causes. 
Sickle cell disease is the cause of CRF in 3 patients (5.17%). 
(Table1). 
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              Table (1) Etiology of chronic renal failure 
 
Cause Case (n=58) Percent 
Unknown 26 44.83 
Obstructive 16 27.52 
Glomerulonephritis 9 15.52 
Hereditary nephropathy 4 6.90 
Sickle cell 3 5.17 
Total no of patient 58 100% 
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3.3 Distribution of children by blood pressure centile: 
       The majority of our patient 44 (75.9%) were found to have 
normal blood pressure, 12 (20.7%) their blood pressure was 
significantly high while only two patients ( 3.4% ) had severe 
hypertension (Table 2) 
 
3.4.1 Glomrulo filtration rate of the study group: 
       The mean GFR for the study group is 34.69 ± 29.3 (range5.58 
- 126.5 ml/min/1.7m 2 ) .  
3.4.2 Serum creatinine of study group: 
       The mean serum creatinine level for the study group is 4.56 
±3.74 (rang 0.5 - 13.8) . 
 
3.5   Duration of illness:  
    The mean duration between diagnosis and dialysis was found to 
be 8.28( ±10.4). Mean of duration since starting management 
18.86 (±22.45),   5 patients were transplanted for less than one 
year , seven patients had kidney transplantation for more than 1 
year . (Table 3) (Figure 7) . 
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Table 2: Blood pressure centile among children under the 
study 
 
Blood pressure centile Case (n=58) Control (n=28) P value 
    
< 90th 44 (75.9%)         28 (100%) 0.018 
90-95th 12 (20.7%) 0  
> 95th 2 (3.4%) 0  
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Table (3): Duration of illness in  the study group : 
   
Mean (SD) 8.28 (10.4) Duration between  
diagnosis and dialysis (months) Rang 1 - 36 months
   
Mean (SD) 18.86 (22.45)Duration since starting 
management, dialysis or conservative (months ago) Rang 1 - 98 months
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3.6  Body Mass Index for Age in cases and control group: 
3.6.1  BMI percentile for Age in cases and control group: 
    Figure 8 Demonstrates the high percentage of under weight in 
children with chronic renal failure as it seen in 33 (57%) of patients 
, while22 (38%) had normal BMI and only 3 patients (5.1%) were 
either  at risk of over weight or  actually over weight .On the other 
side all control were either had a healthy 22 (78.5%) weight or at 
risk of over weight 6 (21.5%). 
3.6.2  BMI using Z score for cases and control: 
     It is shown that 5 (27.8%) of those on conservative 
management 5 (45%) on those on CAPD, 5 (29%) of those on HD 
and 4 (33.3%) from the patient who were transplanted had normal 
weight. Nevertheless all the remaining patients on either type of 
management were showing some degree of thinness (Table 4). 
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Table 4: Body Mass Index for Age using Z score in relation to 
type of management and control group 
 
 
BMI Z score Conservative Chronic Dialysis Transplantation P Case (n=58) Control (n=28) P
Normal 5 (27.8%) 10 (35.7%) 4 (33.3%) 0.83 19 (32.8%) 24 (85.7%) 0.00
Mild thinness 5 (27.8%) 4 (13%) 3 (25%) 12 (20.7%) 4 (14.3%)
Moderate thinness 2 (11.1%) 2 (7.1%) 2 (16.7%) 6 (10.3%) 0
Sever thinness 6 (33.3%) 12 (50%) 3 (25%) 21 (36.2%) 0
Mean (SD) -2.78 (2.95) - 3.0 (3.0) -1.69 (1.8) 0.37 -2.69 (2.8) 0.2 (0.84) 0.00
Range -9.62 - 1.14 -10.40 - 1.14 -4.73 - 2.25 -10.4 - 2.25 -1.38 - 1.43
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 3.7 lipid profile in patients and control: 
3.7 .1 Prevalence of dyslipidemias among different studied 
groups.: 
    Table 5 shows that the prevalence of dyslipidemias varied 
among  the different studied group. Elevated (>95th centile) serum 
cholesterol level was observed in 4patientes (22.2%) of group 
II(conservative) , 
 12(42.9%) of group III(regular dialysis),and 3 patients (25%) of 
group IV (transplanted patients). 
      Border line (75th - 95th centile) serum cholesterol level was 
found in 4 patients (22.2%) of group II, 9(32.1%) of group III, and 
6patients (50%) of group IV. 
    Normal value (5th -75th centile ) of serum cholesterol found in 10 
patients (55.6%) of group II, 7(25%) of group III and  3 patients 
(25%) of group  IV . 
      Elevated serum triglycerides were found in 4patients (22.2%) 
of group II, 13(46.4%) of group III and in 10 (83.3%) of group  IV . 
      Serum triglyceride were found  normal in of 14(77.8%) of group 
II, in 15 (53.6%) patients of group III, and in only 2 patients (16.7%) 
of group  IV. However, it was found normal in all children of group I 
(control group). 
 65
        Elevated LDL was observed in 6 patients (33.3%) of group II, 
11 (39.3%) of group III and in 2 patients (16.7 %) of group IV.  
        The boarder line levels detected in 4 patients (22.2%) of 
group II, 8 (28.6 %) of group III and only 1 patient (8.3%) of group 
IV. 
 LDL showed normal range in 8 (44.4%) of group II, 9 (32.1%) of 
group III, and 9 (75.0%) of group IV , and it was found to be normal 
in all children of group I . 
       HDL was elevated in 5(27.8%) patients of group II, 9(32.1%) 
of group III and none of group IV . 
      HDL show  border line  level in 6 patients (33.3%) of group 
II,9(32.1%) of group III,  in 2 patients (16.7%)of group IV and in 4 
(14.3%) of group I  .  
       Normal levels of HDL was found in 7 patients (38.9%) of group 
II,10 patients (35.7%)of group III,10 patients  (83.3%)of group IV 
and in 24 (85.7%) of group I. 
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Table 5: Prevalence of dyslipidemias among different studied         
              groups 
 
*Normal: 5th – 75th centiles, Borderline: 75th -95th centiles, High: >95th centile. 
 
 
 
 
 
 
Lipid profiles level Conservative
(n=18) 
ChronicDialysis
(n=28) 
Transplantation
(n=12) 
Controls 
(n=28) 
Normal 10 (55.6%) 7 (25%) 3 (25%) 28 (100%) 
Borderline 4 (22.2%) 9 (32.1%) 6 (50%)
Elevated 4 (22.2%) 12 (42.9%) 3 (25%)
Cholesterol*  
 
Normal 14 (77.8%) 15 (53.6%) 2 (16.7%) 28 (100%) 
Elevated  4 (22.2%) 13 (46.4%) 10 (83.3%)
Triglycerides 
 
LDL  Normal 8 (44.4%) 9 (32.1%) 9 (75.0%) 28 (100%) 
 Borderline 4 (22.2%) 8 (28.6%) 1 (8.3%)
 Elevated 6 (33.3%) 11 (39.3%) 2 (16.7%)
  
HDL Normal  7 (38.9) 10 (35.7%) 10 (83.3%) 24(85.7%) 
 Borderline 6 (33.3) 9 (32.1%) 2 (16.7%) 4 (14.3%)
 Elevated 5 (27.8) 9 (32.1%)
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3.7.2  Comparison between the mean value of the studied  
lipid profiles in patients groups versus control group: 
    Our results show that the  mean values of all lipid profiles 
studied , except HDL, were significantly  high in all patients when 
compared to control group .In contrast the mean values of all lipid 
profile were within normal range in control  group (p 
value<0.05).(Table 6), 
(Figure 9). 
3.7.3  Comparison between mean values of lipid profile among 
patients of different types of management: 
    (Table 7) shows There were no significant difference in serum 
lipid profiles between patients having different types of 
management,  
    Ninety five percent (95%) Confidence interval(CI) of all lipid 
profiles ;except HDL, in all patients was significant as compared to 
control group .This was observed regardless of the type 
management Figure (10.a),(10.b),(10-c),(10-d),(10-e). 
 
 
 
 
 
 
 
 
 
 68
 
Table 6: Comparison between the mean (SD) (min - max) 
values of lipid profile in patients groups  versus control group 
 
 patients (n=58) controls (n=28) P value 
Serum cholesterol 184.75 (34.3) 135.21(17.3) 0.0
 129 - 280 100 - 156  
    
Serum triglycerides 118.19 (34.9) 90.21(14.9) 0.0
 64 - 192 64 - 117  
    
VLDL 23.63 (6.98) 18.04 (2.99) 0.0
 12.8 - 38.4 12.8 - 23.4  
    
LDL 115.75 (36.54) 72.35(11.46) 0.0
 39 - 207 55 - 93  
    
HDL 46.4 (20.57) 49.14 (3.52) 0.4
 22 - 128 44 - 55  
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Table 7: Comparison between the mean (SD) (min - max) values 
of lipid profile among patients with different types of management  
Lipid profile Conservative Chronic dialysis Transplantation P value
Serum cholesterol 172.16 (32.2) 192.78 (36.3) 184.9 (29.2) 0.13
 135 - 266 129 – 280 132 - 225  
     
Serum triglycerides 108.05 (33.9) 120.03 (38.0) 129.1 (26.1) 0.25
 70 - 186 64 - 192 80 - 182  
     
VLDL 21.6 (6.8) 24.00 (7.6) 25.8 (5.2) 0.25
 14.0 - 37.2 12.0 – 38.4 16.0 - 36.4  
     
LDL 111.9 (41.2) 125.42 (36.4) 98.9 (21.4) 0.93
 40 - 190 39 - 207 80 - 136  
     
HDL 49 (28.5) 42.5 (18.0) 51.58 (7.2) 0.36
 23 - 128 22 - 115 41 - 65  
     
Significant P value <0.05 
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 Figure 10a Mean and 95% Confidence interval of Serum Cholesterol in relation to 
type of management and control group 
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 Figure 10b Mean and 95% Confidence interval of Serum Triglycerides (TG) in 
relation to type of management and control group 
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 Figure 10c Mean and 95% Confidence interval of Serum Very Low Density 
Lipoproteins (VLDL) in relation to type of management and control group 
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 Figure 10d Mean and 95% Confidence interval of Serum Low Density Lipoprotein 
(LDL) in relation to type of management and control group 
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 Figure10e Mean and 95% Confidence interval of Serum High Density Lipoprotein 
(HDL) in relation to type of management and control group 
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3.7.4  Comparison of lipid profile in conservative (group II) 
versus control (group1): 
  (Table 7.1) shows that the mean values of serum cholesterol and 
LDL in conservatively managed patients (group II) was significantly 
elevated compared to control group (p=0.00). While the difference 
in the values of the serum triglyceride level and VLDL between 
patients and control was significant (p=.048) of both.  
3.7.5 Comparison between the mean value of lipid profile of 
patients on chronic dialysis (group II) versus controls (group I 
): 
     The mean values of all lipid profiles, with exception of HDL 
were significantly elevated in chronic dialysis patients compared to 
control group (p=0.00) as shown in (Table 7.2) 
3.8.5 Comparison between the mean values of lipid profile of 
patients on Transplantation versus controls: 
 
     (Table 7.3) shows that the mean values of all lipid profiles, 
exception of HDL ,were significantly elevated in transplant group 
as compared to control (p=0.00).    
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Table 7.1: Comparison between the mean (SD) (min - max) 
values of lipid profile of patients on Conservative treatment 
versus controls 
 
Lipid profile Conservative (n=18) Control (n=28) P value 
Serum cholesterol 172.16 (32.2) 135.21 (17.2) 0.00
 135 – 266 100 - 156  
    
Serum triglycerides 108.05 (33.9) 90.21 (14.9) 0.048
 70 – 186 64 - 117  
    
VLDL 21.6 (6.8) 18.04 (2.99) 0.048
 14.0 - 37.2 12.8 - 23.4  
    
LDL 111.9 (41.2) 72.35 (11.4) 0.00
 40 – 190 55 - 93  
    
HDL 49 (28.5) 49.14 (3.52) 0.983
 23 – 128 44 - 55  
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Table 7.2: Comparison between the mean (SD) (min - max) 
values of lipid profile of patients on chronic dialysis versus 
controls 
 
Lipid profile Regular Dialysis 
(n=28) 
Controls P value 
Serum cholesterol 192.78 (36.3) 135.2 (17.3) 0.00
 129 – 280 100 - 156  
    
Serum triglycerides 120.03 (38.0) 90.21(14.93) 0.00
 64 – 192 64 - 117  
    
VLDL 24.00 (7.6) 18.0 (2.9) 0.00
 12.8 – 38.4 12.8 – 23.4  
    
LDL 125.42 (36.4) 72.35 (11.46) 0.00
 39 – 207 55 - 93  
    
HDL 42.5 (18.0) 49.14 (3.52) 0.66
 22 – 115 44 - 55  
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Table 7.3: Comparison between the mean (SD) (min - max) 
values of lipid profile of patients on Transplantation versus 
controls 
 
Lipid profile Transplantation (n=12) Control (n=28) P value
Serum cholesterol 184.92 (17.28) 135.21 (17.2) 0.00
 132 – 225 100 - 156  
    
Serum triglycerides 129.08 (26.11) 90.21 (14.9) 0.00
 80 – 182 64 - 117  
    
VLDL 25.82 (5.22) 18.04 (2.99) 0.00
 16 – 36.4 12.8 - 23.4  
    
LDL 98.9 (21.45) 72.35 (11.4) 0.00
 80 – 136 55 - 93  
    
HDL 51.58 (7.24) 49.14 (3.52) 0.28
 41 – 65 44 - 55  
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3.8 Correlation between lipid profile in CAPD and HD  : 
      When comparing serum lipid profile between CAPD and HD we 
observed that serum cholesterol was significantly elevated in  
CAPD  as compared to HD group (p=0.02) , regarding TG 
,LDL,VLDL and HDL there was no significant difference as shown 
in (Table 8) 
3.9 Correlation between lipids profiles, GFR among patients: 
 
     (Table 9) shows that there is a negative relation between LDL 
and   GFR, that is when GFR decrease LDL value increase which 
is statistically significant (p=0.016), while no such correlation was 
reported between other lipids and GFR. 
3.10 Correlation between lipid profile and durations among   
     patients : 
        It found that Serum cholesterol increase with increasing in the 
duration between diagnosis and dialysis .However a negative 
correlation exists between Serum cholesterol and duration since 
starting management, dialysis or conservative(Table 10)  
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Table 8: Comparison between the mean (SD) (min - max) 
values of lipid profile in relation to CAPD and HD 
 
 
Lipid Profile CAPD HD P value 
Serum cholesterol 211.18 (39.06) 180.88 (29.7) 0.02
 169 - 280 129 - 215  
    
Serum triglycerides 127.8 (48.2) 115 (30.3) 0.44
 64 - 192 64 - 164  
    
VLDL 25.56 (9.6) 23 (6.1) 0.44
 12.8 - 38.4 12.8 - 32.8  
    
LDL 135.45 (47.8) 118.94 (26.3) 0.31
 39 - 207 75 - 169  
    
HDL 49.36 (22.8) 38.06 (13.16) 0.10
 31 - 115 22 - 70  
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Table9: Correlation between lipid profile and GFR 
among cases  
 
Lipid profile          r*     p value* 
   
Serum cholesterol       - 0.23       0.08 
   
Serum triglycerides         -0.05         0.7 
    
VLDL          -0.05          0.7 
    
LDL          -0.31        0.016 
   
HDL          0.120         0.37 
    
*r: Pearson’s Correlation Coefficient, P value: Level of sig 
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Table 10: Correlation between lipid profile and durations 
among cases  
 
  Dur1 Dur2 
Serum cholesterol     r 0.47 -0.29 
      p  0.01 0.05 
Serum 
triglycerides      r -0.09 -0.07 
      p  0.65 0.63 
VLDL      r -0.09 -0.07 
       p  0.65 0.63 
LDL      r 0.32 -0.26 
       p  0.10 0.08 
HDL       r 0.31 0.11 
      p  0.11 0.49 
              *r: Pearson’s Correlation Coefficient, P value: Level of significance 
 
              Dur 1: Duration between diagnosis and dialysis (months) 
              Dur 2: Duration since starting management, dialysis or conservative  
                   (months ago) 
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Chapter Four 
 
4- DISCUSSION 
 
   Dyslipidemia is a primary risk factor for cardiovascular disease 
and a common complication of progressive kidney disease. It 
contributes to cardiovascular mortality, which is 10 to 20 times higher 
in dialysis patients than in normal population even after adjustments 
are made for age and sex (50)(51) . 
     Dyslipidemia complicating renal disease have attracted the 
interest of many investigators and both qualitative and quantitative 
abnormalities in lipid profiles have been noted in patient with chronic 
renal failure (3) . 
Sociodemographic Characteristics:  
The mean age of the study group was found to be 11.37 ± 4.2 
years, the majority (28 ±48.3%) were found to be older than 12 year 
of age. Similar age pattern was found in studies done by Elnur who  
found that  (56.6%) of ESRD children aged between 10 to 15 years  
(88) . 
The incidence of renal failure was common in males with a 
male to female ratio 1.6:1. This is similar to what was reported in 
North Africa countries (10), and in   Tunisia where male: female ratio 
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of 1.83:1 was found (11). The predominance of males has been shown 
in unpublished data by Mohamed A (14) and Abdellraheem MB  (19) in 
Sudanese children . This is most likely due to the increased incidence 
of urinary tract abnormalities seen in males. 
In our study  we found that most of the patients 26 (44.8%) 
resided in Khartoum, and this might be due to that children with CRF 
from other states are referred to Khartoum to be diagnosed and 
treated. 
This was in agreement A. Rahman found that (28.8%) of the 
patients were resided in Khartoum (14) .  Elnur also found that most of 
her patients 38 (58.3%) resided in Khartoum (88) . 
   
Etiology of CRF:  
Most of our children   (44.8%) had unknown causes for their 
renal failure. A similar percentage was reported before from Sudan by 
Abdelraheem MB who reported uncertain causes for CRF in 49.1% of 
his patients (19) .  This may be due to the late presentation to health 
facilities, so the clinical picture of the primary disease becomes 
masked by the clinical symptoms of CRF. When renal biopsy, if ever 
done, mainly yields no information.  
Obstructive uropathy was detected in 16 patients (27.5%). This 
is higher compared to what was detected by Mohamed A.  In her 
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study she found that renal calculi constituted 7.5%of causes of CRF  
(14) .   This may be because she fragmented Obstructive uropathy in to 
separate entities. 
Glomerulonephritis was responsible for CRF in (15.52%), this 
was completely different from what was reported by Mohamed A in 
Sudan. she found that GN was a cause of CRF in (52.2%)  (14) .   This 
difference can be attributed to the recent advancement in the 
diagnosis and management of GN. Barsoum in North Africa (10) 
countries and studies from Tunisia (11)  reported a percentage of 16.4 
% which is approximating ours.  
Four patients (6.90%) had hereditary causes. This is less than 
what was reported by USRDS which was 24.45%  (89) ,  this may be 
because of our late diagnosis of these conditions as they are rare. 
Treatment modality: 
In this study, most of the patients 18(31%) were in conservative 
managements, 17 (29%) of the study group were on haemodialysis 
(HD), 12(21%) transplanted and 11(19%) patient on continuous 
ambulatory peritoneal dialysis (CAPD). In previous study done by 
Mohammed Babiker 2004 although most of the patients were on 
hemodialysis (59.6%)(19) . He had no CAPD paediatric patients, as it 
was not introduced yet as a modality of management. In our study the 
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presence of CAPD patients can be due to the improving awareness of 
CAPD as a good modality of management of CRF in children. In our 
study 28 patients (48 %) were on regular dialysis; either HD or 
CAPD; compared to 18 patients on conservative management (31 %) 
and 12 transplanted patients (21 %). This large number on regular 
dialysis can be due to the poor facilities allowing transplantation.  
Lipid profile among case and control in relation to treatment 
modalities: 
Prevalence of dyslipidemias among different studied groups: 
The result of this study showed the prevalence and pattern of 
dyslipidemia in Sudanese children with CRF. Our findings are 
compared with the result of other studies which examined 
abnormalities of lipid metabolism in children with CRF. However 
data about this problem is scanty in children; most of the published 
data is from adult studies.  
        In our study we studied the behavior of various lipid fractions. 
We reported that elevated serum cholesterol levels were observed in 
(22.2%) of group II (conservative) and (42.9%) of group III (regular 
dialysis).  Elevated LDL was observed in (33.3%) of group II and 
(39.3%) of group III. Querfeld stated that serum level of total 
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cholesterol, VLDL, and LDL are frequently elevated in children with 
chronic renal failure (78) .  
This is consistent with our findings. Our results differ from the 
study done in Egypt by Mohamed Ragab and Amany Ragab about 
lipid abnormalities in children with CRF in two group; conservative 
managed group (divided in to <10years and >10 years) and 
haemodilayzed group. They observed that serum cholesterol levels 
were elevated in 28% of conservatively managed children and LDL 
was high only in 28% of children >10 years old (77) .  Our lower 
percentage can be due to that we are not including the patients with 
boarder line cholesterol levels. 
 We reported normal values of serum cholesterol in (55.6%) of 
group II and in  (25%) of group III. Normal LDL was found in 
(44.4%) of group II, and (32.1%) of group III. In Kuwait Al-Rashidi 
M. in his study on adult patients found that there is a general trend 
towards significant (p value < 0.05) increases in post-dialysis TC, 
HDL and LDL in both diabetic and non-diabetic groups. They 
speculated that with repeated dialysis, dyslipidaemia may get 
progressively worse (83) . This speculation justifies our finding of 
normal cholesterol in more than half of the conservatively managed 
patients who did not start dialysis, compared to just one quarter of 
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patients on regular dialysis having normal cholesterol levels. This 
speculation can be applied to all other lipid fractions. 
  Regarding triglycerides levels we found that elevated serum 
triglycerides were found in 4 patients (22.2%) of group II, 13 patients 
(46.4%) of group III and in 10 patients (83.3%) of group IV. 
Consistent with the study of  K. Asayama et al.  who found increased 
triglycerides levels in a group of children with CRF on conservative 
and haemodialysis management(80) .  Also ZL Papadopoulou in his 
study found a significant (P < 0.05) increase in triglyceride levels in 
children on maintenance hemodialysis (81).  This also agrees with what 
was found by Nelva T. when he studied CRF adult patients on regular 
hemodialysis. He found that these patients have a gradual 
deterioration in triglycerides levels a finding that might be relevant to 
the risk of cardiovascular disease in this setting (84). 
We observed Elevated serum triglycerides in 4 patients (22.2%) 
of the conservatively managed group and in 13 patients (46.4%) of the 
regular dialysis group .This is different than what was reported in 
Egypt by Mohamed Ragab and Amany Ragab in their study about 
lipid abnormalities in children with CRF. They found that elevated 
serum triglycerides were found in 77 % of the haemodialyzed. 
Triglycerides were found to be high in 60% of children<10 years and 
in about 40% of children>10 years (77). 
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Our results of triglycerides levels in the conservatively managed 
patients and those on regular dialysis were different than what was 
reported by   Ravichandran RR, who studied the behavior of various 
lipid fractions in adults. He found that the fasting serum triglycerides 
were significantly elevated in both conservatively managed (50%) and 
dialyzed patients (35%) with a p value of < 0.02 (87) . The explanation 
of this difference may be related to the different age groups and to the 
dietary pattern in the form of high intake of polyunsaturated fatty 
acids in his study population.  
        In our study normal levels of HDL were found in 38.9% of group 
II, 35.7% of group III, and in 83.3% of group IV. Border line of HDL 
level was detected in 33.3% of group II and 32.1% of group III. Other 
studies documented that low HDL was found in most of patients with 
CRF.  Querfeld  found low HDL levels in the majority of patients 
with CRF (78) .  ZL Papadopoulos et al detected significant decrease in 
HDL in his conservatively managed and hemodialysis groups (81) . 
Mohamed Ragab and Amany Ragab in their study found low LDL 
level in 90% of the haemodialysis group (77) . K. Asayama reported 
that HDL level was correlated inversely with serum triglyceride level 
and positively with glomerular filtration rate (80). This can be 
attributed to the fact that the management can be of short duration to 
affect the HDL level.  
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 Comparison between the lipid profiles in relation to the type of         
 management :  
The mean of all serum lipid profiles were significantly elevated 
in the studied groups; with exception of HDL; when compared to the 
control group. This goes with what was reported by K Asayama et al, 
(80).  ZL Papadopoulou (81) and Querfeld  (78) .  This also goes with adult 
study done by Shah B, Nair Swhen. They studied dyslipidemia in 
patients with CRF and in renal transplant patients. They had 4 groups 
patients group I (control subjects), group II (CRF patients on 
conservative treatment), group III (ESRD patients on HD) and group 
IV (post-renal transplant patients). They found that significant 
hypertriglyceridemia does develop in a majority of CRF patients (p 
value <0.05) (86) . It was consistent with what was found by 
Ravichandran RR and others when they studied the behavior of 
various lipid fractions in CRF patients. Three groups of patients were 
included in their study; controls (Group I), conservatively managed 
(Group II) and those on regular hemodialysis (Group III). They found 
that. The fasting serum triglycerides were significantly elevated in 
both the groups of renal failure patients (p < 0.02) (87) . 
Comparison of lipid profiles in different patient groups: 
We observed no significant differences in the mean of all serum 
lipid profiles between different groups of patients. This was also 
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reported by K. Asayama, et al (80) and  ZL Papadopoulou who  
observed that there were no significant differences in the beta 
lipoproteins (LDL) in maintenance hemodialysis compared to the 
conservative and control groups(81). But Mohamed Ragab and Amany 
Ragab found that abnormalities in basic lipid profiles were more 
frequently detected in children with CKD under regular hemodialysis 
than those on conservative therapy only (77) . This is agreed with what 
was found in our study.  
Comparison between group III a (HD) and group III b (CAPD): 
In our study the serum cholesterol was significantly elevated in 
CAPD patients than in HD patients (p value < 0.02). There was no 
significant difference in triglycerides, LDL, VLDL and HDL. This is 
similar to what Avram MM and his colleagues stated when they 
studied the lipid profile in HD adult patients in comparison to that in 
CAPD patients. They found that total cholesterol (TC) and high-
density lipoprotein cholesterol (HDL-C) were significantly higher (p 
value < 0.05)(85) . 
Lipid profile in patients with kidney transplant:  
Out of 12 patients who had kidney transplant 10 patients 
(83.3%) had elevated serum triglyceride levels. Concerning serum 
cholesterol it was boarder line in 6 patients (50%) and high in 3 
patients (25%). This is similar to what was found in a study done by 
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L. F. Saldanha and others on hyperlipidemia after renal 
transplantation in children, who stated that 50 % of patients showed 
an elevated lipoprotein (82).  But unlike what was found by the study 
done by Shah B et al, who studied dyslipidemia in adult patients with 
chronic renal failure and in renal transplant patients. He found 
normal triglyceride in post transplant patients (86) . The high level of 
triglycerides in our patients can be explained by the use of high doses 
of steroids following kidney transplantation.          
         Although our result showed significant abnormalities in basic 
lipid profile in the studied groups compared to control other studies in 
adults stressed that disturbances in lipid metabolism associated with  
CRF were mainly in the form of dyslipoproteinemias rather than 
dyslipidemia, and such abnormalities will be reflected on 
apolipoprotein composition rather than lipid profile. 
           We reported an inversely proportionate relation between LDL 
and   GFR that is when GFR decrease LDL value increase. We also 
found that Serum cholesterol increase is directly proportionate to the 
increase in the duration between diagnosis and dialysis.  
           The dangers of high lipid profiles in CRF patients do not only 
contribute to the accelerated atherosclerosis but may enhance the 
progression of renal disease in patients with residual renal function. 
Abnormalities in lipid profile can be detected in children with CRF 
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with variant degrees of renal insufficiency. It is recommended to 
evaluate dyslipidemia more frequently in CRF children than in 
general population and this may be extended to apoprotein profiles. 
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Conclusions 
? The mean of all lipid profiles, except HDL were significant 
elevated in all patients with chronic renal failure on different 
treatment modalities. 
? There are no significant differences in the lipid profile 
abnormalities in patients with chronic renal failure on different 
treatment modulate. 
? Patients with chronic renal failure on conservative management 
showed elevation in   the mean values of all lipid profiles. 
? Patients on chronic dialysis, showed significant elevation in    
the mean values of all lipid profiles, except HDL. 
? Patients had kidney transplant showed significant elevation in    
the mean values of all lipid profiles, except HDL. 
? The relation between the GFR and lipids abnormalities was 
insignificant except for LDL which showed a significant 
negative correlation with the GFR.  
? The duration between the diagnosis and the initiation of 
treatment of CRF is positively correlated with hyperlipidemia. 
? The duration of CRF treatment affects hyperlipidemia 
positively especially for hypercholesterolemia which decreases 
with the duration of the treatment. 
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Recommendations 
 
 
 
? Hyperlipidemia is major problem in patients with chronic 
renal failure, which affects their overall outcome by greatly 
increasing the risk of cardiovascular events, hence should be 
recognized and treated early in the course of the disease. 
? Assessment of lipid profile is advised as an early and routine 
investigation in all patients with chronic renal failure. 
? Early initiation of treatment for hyperlipidemia in patients 
with chronic renal failure is highly recommended regardless of 
the type of treatment they are running. This is believed to 
improve the outcome by reducing associated complications 
especially the cardiovascular ones. 
? Provision of necessary laboratory facilities in all renal centers 
that will encourage early assessment of lipid profiles in the 
face of their high cost. 
? As the use of lipid-lowering drugs in children is controversial a 
good diet control to decrease lipid intake may help. 
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University of Khartoum 
Faculty of Medicine 
    Department of Pediatrics and Child Health 
Postgraduate Medical Studies Board  
HYPERLIPEDEMIA:  THE INCIDANCE   AND THE EFFECT OF 
TREATMENT IN CHILDERNS WITH CRF IN KHARTOUM STATE 
Questionnaire  
                  Serial No……………………………………………………………………. 
                  Date …………………………………………………………………………… 
              Personal Data 
• Name of the child………………………………………………………… 
•  Age  ……………………………………………..   
• Gender               Male = 1                      Female = 2 
•  Tribe  …………………………………………………………………….. 
• Ethinc group        1.Arab         2.african         3.afroarab            4.others 
• Residence in Khartoum state             Khartoum= 1       Omdurman= 2          Bahri= 
3           others =4 (specify) 
            
            Drug history 
                 Steroids =1                    Diuretics =2              Antihypertensive =3 
                Cyclosporine or Cyphosphamide       =4 
                Others (Specify)   =5  ……………………….. 
              Diagnosis of CRF 
                  (GFR (mL/min/1.73 m2) = k (Height) / Serum Creatinine) 
• Classification of CRF 
• Mild =1           Moderate=2            Severe=3     ESRF=4 
• Causes of CRF ……………………………………………………… 
• Date of diagnosis of CRF ……………………………………….. 
           
 
 
 
 
 
 2
 
 
  Examination  
•  BP                <90th =1          90-95th =2                    >95th =3       >99th  =4 
•  H.T …………………………………………..              
•  WT  ……………………………………………………..          
               Signs of hyperlipidemia 
                   Tendon xanthomas=1                corneal arcus=2         
              Management of CRF 
o  Conservative treatment    
                              Diet Control                                               Yes=1                   No=2 
                              Drug treatment 
? Antihypertensive                         Yes=1                    No=2 
                                     If yes what type 
•   ACE inhibitor                      Yes=1                   No=2      
•   Ca channel blocker             Yes=1                  No=2 
•   Loop diuretics                     Yes=1                   No=2         
•   B. Blockers                          Yes=1                   No=2 
•   Others                                   Yes=1                   No=2 
? Other drugs                                   Yes=1                   No=1                                                      
if yes specify …………………………. 
o Dialysis                                                                                             
•  Type of dialysis                          PD=1         HD =2         CAPD=3  
•   Date started the dialysis ……………………………….. 
•   Duration of the dialysis………………………………….. 
•  Duration between diagnosis and dialysis………….. 
•  Regularity of dialysis             regular=1                  irregular=2 
o Transplantation     
• Duration of transplantation    
                              < 6 months=1    6 -12 months=2     12months 
• Drugs used 
                                              Prednisone                            Yes=1                   No=1 
                                              Cyclosporine                         Yes=1                   No=1 
                                              Azothioprine                         Yes=1                   No=1 
                                              Others  (specify) ……………  Yes=1                   No=1 
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Investigations  
• S. Creatinine …………………………………….        
•  S  Cholesterol ……………………………… 
•  S.TG………………………………………. 
• VDL ………………………………………… 
• LDL………………………………………… 
• HDL………………………………………….. 
 
                                       
 
 
 
 
 
 
 
 
 
 
